AU2009308182B2 - Biodefenses using triazole-containing macrolides - Google Patents

Biodefenses using triazole-containing macrolides Download PDF

Info

Publication number
AU2009308182B2
AU2009308182B2 AU2009308182A AU2009308182A AU2009308182B2 AU 2009308182 B2 AU2009308182 B2 AU 2009308182B2 AU 2009308182 A AU2009308182 A AU 2009308182A AU 2009308182 A AU2009308182 A AU 2009308182A AU 2009308182 B2 AU2009308182 B2 AU 2009308182B2
Authority
AU
Australia
Prior art keywords
cem
compounds
effective amount
group
azi
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2009308182A
Other languages
English (en)
Other versions
AU2009308182A1 (en
Inventor
Prabhavathi Fernandes
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cempra Pharmaceuticals Inc
Original Assignee
Cempra Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cempra Pharmaceuticals Inc filed Critical Cempra Pharmaceuticals Inc
Publication of AU2009308182A1 publication Critical patent/AU2009308182A1/en
Priority to AU2016202707A priority Critical patent/AU2016202707A1/en
Application granted granted Critical
Publication of AU2009308182B2 publication Critical patent/AU2009308182B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/424—Oxazoles condensed with heterocyclic ring systems, e.g. clavulanic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • C07H17/04—Heterocyclic radicals containing only oxygen as ring hetero atoms
    • C07H17/08—Hetero rings containing eight or more ring members, e.g. erythromycins
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
AU2009308182A 2008-10-24 2009-10-24 Biodefenses using triazole-containing macrolides Ceased AU2009308182B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2016202707A AU2016202707A1 (en) 2008-10-24 2016-04-28 Biodefenses using triazole-containing macrolides

Applications Claiming Priority (13)

Application Number Priority Date Filing Date Title
US10816808P 2008-10-24 2008-10-24
US10811008P 2008-10-24 2008-10-24
US10813408P 2008-10-24 2008-10-24
US10813708P 2008-10-24 2008-10-24
US10811208P 2008-10-24 2008-10-24
US61/108,112 2008-10-24
US61/108,134 2008-10-24
US61/108,137 2008-10-24
US61/108,168 2008-10-24
US61/108,110 2008-10-24
US16210909P 2009-03-20 2009-03-20
US61/162,109 2009-03-20
PCT/US2009/061978 WO2010048601A1 (en) 2008-10-24 2009-10-24 Biodefenses using triazole-containing macrolides

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2016202707A Division AU2016202707A1 (en) 2008-10-24 2016-04-28 Biodefenses using triazole-containing macrolides

Publications (2)

Publication Number Publication Date
AU2009308182A1 AU2009308182A1 (en) 2010-04-29
AU2009308182B2 true AU2009308182B2 (en) 2016-05-19

Family

ID=42119711

Family Applications (4)

Application Number Title Priority Date Filing Date
AU2009308182A Ceased AU2009308182B2 (en) 2008-10-24 2009-10-24 Biodefenses using triazole-containing macrolides
AU2009308180A Ceased AU2009308180B2 (en) 2008-10-24 2009-10-24 Methods for treating gastrointestinal diseases
AU2009308181A Ceased AU2009308181B2 (en) 2008-10-24 2009-10-24 Methods for treating resistant diseases using triazole containing macrolides
AU2016202707A Abandoned AU2016202707A1 (en) 2008-10-24 2016-04-28 Biodefenses using triazole-containing macrolides

Family Applications After (3)

Application Number Title Priority Date Filing Date
AU2009308180A Ceased AU2009308180B2 (en) 2008-10-24 2009-10-24 Methods for treating gastrointestinal diseases
AU2009308181A Ceased AU2009308181B2 (en) 2008-10-24 2009-10-24 Methods for treating resistant diseases using triazole containing macrolides
AU2016202707A Abandoned AU2016202707A1 (en) 2008-10-24 2016-04-28 Biodefenses using triazole-containing macrolides

Country Status (11)

Country Link
US (7) US9072759B2 (cg-RX-API-DMAC7.html)
EP (4) EP2365747B1 (cg-RX-API-DMAC7.html)
JP (10) JP5602748B2 (cg-RX-API-DMAC7.html)
CN (4) CN102223794B (cg-RX-API-DMAC7.html)
AU (4) AU2009308182B2 (cg-RX-API-DMAC7.html)
DK (1) DK2358379T3 (cg-RX-API-DMAC7.html)
ES (3) ES2676168T3 (cg-RX-API-DMAC7.html)
HK (1) HK1252140A1 (cg-RX-API-DMAC7.html)
HR (1) HRP20160222T1 (cg-RX-API-DMAC7.html)
SI (1) SI2358379T1 (cg-RX-API-DMAC7.html)
WO (3) WO2010048600A1 (cg-RX-API-DMAC7.html)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004080391A2 (en) 2003-03-10 2004-09-23 Optimer Pharmaceuticals, Inc. Novel antibacterial agents
JP5698979B2 (ja) 2007-10-25 2015-04-08 センプラ ファーマシューティカルズ，インコーポレイテッド マクロライド系抗菌剤の調製プロセス
HRP20160222T1 (hr) 2008-10-24 2016-04-08 Cempra Pharmaceuticals, Inc. Biozaštite uporabom makrolida koji sadrže triazol
US9937194B1 (en) 2009-06-12 2018-04-10 Cempra Pharmaceuticals, Inc. Compounds and methods for treating inflammatory diseases
WO2011032052A1 (en) 2009-09-10 2011-03-17 Cempra Pharmaceuticals, Inc. Methods for treating malaria, tuberculosis and mac diseases
KR102006200B1 (ko) * 2010-03-22 2019-08-01 셈프라 파마슈티컬스, 인크. 매크로라이드의 결정 형태들 및 그 용도들
EP2571506B1 (en) 2010-05-20 2017-05-10 Cempra Pharmaceuticals, Inc. Processes for preparing macrolides and ketolides and intermediates therefor
KR20130120458A (ko) 2010-09-10 2013-11-04 셈프라 파마슈티컬스, 인크. 질환을 치료하기 위한 수소결합 형성 플루오로 케토라이드
WO2013148891A1 (en) 2012-03-27 2013-10-03 Cempra Pharmaceuticals, Inc. Parenteral formulations for administering macrolide antibiotics
EP2968801B1 (en) * 2013-03-14 2018-09-26 Cempra Pharmaceuticals, Inc. Methods for treating respiratory diseases and formulations therefor
CN105188712A (zh) 2013-03-15 2015-12-23 森普拉制药公司 用于制备大环内酯抗菌剂的收敛方法
AU2014248014B2 (en) * 2013-04-04 2018-11-08 President And Fellows Of Harvard College Macrolides and methods of their preparation and use
CN104151382B (zh) * 2014-08-08 2016-09-14 广东东阳光药业有限公司 一种固态大环内酯的晶型
CN104311611B (zh) * 2014-08-13 2017-01-18 广东东阳光药业有限公司 一种制备固态大环内酯的方法
JP2017531663A (ja) 2014-10-08 2017-10-26 プレジデント アンド フェローズ オブ ハーバード カレッジ １４員ケトライドならびにそれらの調製および使用の方法
EP3273969A4 (en) * 2015-03-25 2018-11-21 President and Fellows of Harvard College Macrolides with modified desosamine sugars and uses thereof
CN106554992A (zh) * 2015-09-28 2017-04-05 中国疾病预防控制中心传染病预防控制所 检测耐红霉素弯曲菌的试剂盒
BR112019017223A2 (pt) * 2017-02-17 2020-04-14 Cempra Pharmaceuticals Inc macrolídeos contendo triazol e seus usos oftálmicos
US10706191B2 (en) * 2017-08-31 2020-07-07 Google Llc Systems and methods for generating a geo-level hierarchical Bayesian model
US11145299B2 (en) 2018-04-19 2021-10-12 X Development Llc Managing voice interface devices

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060100164A1 (en) * 2003-03-10 2006-05-11 Chang-Hsing Liang Novel antibacterial agents

Family Cites Families (128)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1354753A (en) 1919-02-11 1920-10-05 E M Lannes Portable building
US2180006A (en) 1936-09-09 1939-11-14 Eastman Kodak Co Process for the separation and refining of amines
GB891817A (en) 1959-04-07 1962-03-21 Upjohn Co Improvements in or relating to injectable tetracyclic preparations
US3843787A (en) 1969-01-15 1974-10-22 Pierrel Spa Water soluble derivative of erythromycin
US3668282A (en) 1970-05-08 1972-06-06 Stauffer Chemical Co Stabilized mixture employing n-(beta-0,0-dialkyldithiophosphoryl) aryl sulfonamides
SE458505B (sv) 1979-07-10 1989-04-10 Lepetit Spa Anvaendningen av rifamycin sv och salter daerav foer framstaellning av en beredning foer behandling av reumatoid artrit samt vissa av salterna och deras framstaellning
US4331803A (en) * 1980-06-04 1982-05-25 Taisho Pharmaceutical Co., Ltd. Novel erythromycin compounds
US4474768A (en) 1982-07-19 1984-10-02 Pfizer Inc. N-Methyl 11-aza-10-deoxo-10-dihydro-erytromycin A, intermediates therefor
JPS59175414A (ja) 1983-03-23 1984-10-04 Toyo Jozo Co Ltd マクロライド抗生物質の安定な経口用製剤および安定化法
US4742049A (en) 1986-06-04 1988-05-03 Abbott Laboratories Semisynthetic erythromycin antibiotics
KR960000434B1 (ko) 1986-12-17 1996-01-06 다이쇼 세이야꾸 가부시끼가이샤 에리스로마이신 a유도체 및 그의 제조 방법
HU198913B (en) 1987-09-03 1989-12-28 Pliva Pharm & Chem Works Process for producing 10-dihydro-10-deoxo-11-aza-erythronolide a-derivatives and pharmaceutical compositions containing them as active components
BE1001869A3 (fr) 1988-10-12 1990-04-03 Franz Legros Procede d'encapsulation liposomiale d'antibiotiques aminoglucosidiques, en particulier de la gentamycine.
IL99995A (en) 1990-11-21 1997-11-20 Roussel Uclaf Erythromycin derivatives, their preparation and pharmaceutical compositions containing them
US5985844A (en) * 1992-03-26 1999-11-16 Merck & Co., Inc. Homoerythromycin A derivatives modified at the 4"-and 8A-positions
FR2697524B1 (fr) 1992-11-05 1994-12-23 Roussel Uclaf Nouveaux dérivés de l'érythromycine, leur procédé de préparation et leur application comme médicaments.
US5527780A (en) 1992-11-05 1996-06-18 Roussel Uclaf Erythromycin derivatives
FR2718450B1 (fr) * 1994-04-08 1997-01-10 Roussel Uclaf Nouveaux dérivés de l'érythromycine, leur procédé de préparation et leur application comme médicaments.
FR2719587B1 (fr) 1994-05-03 1996-07-12 Roussel Uclaf Nouveaux dérivés de l'érythromycine, leur procédé de préparation et leur application comme médicaments.
US5834428A (en) 1995-04-14 1998-11-10 1149336 Ontario Inc. Glucagon-like peptide-2 and its therapeutic use
WO1997001532A1 (en) * 1995-06-28 1997-01-16 Tokuyama Corporation Ketonitrile derivatives and antibacterial agent and drug containing the same
FR2739620B1 (fr) * 1995-10-09 1997-12-19 Roussel Uclaf Nouveaux derives de la 5-0-desosaminyl 6-o-methyl erythronolide a, leur procede de preparation et leur application a la preparation de produits biologiquement actifs
US6274715B1 (en) 1995-11-08 2001-08-14 Abbott Laboratories Tricyclic erythromycin derivatives
US5742049A (en) * 1995-12-21 1998-04-21 Bruker-Franzen Analytik Gmbh Method of improving mass resolution in time-of-flight mass spectrometry
FR2742757B1 (fr) * 1995-12-22 1998-01-30 Roussel Uclaf Nouveaux derives de l'erythromycine, leur procede de preparation et leur application comme medicaments
FR2745290B1 (fr) * 1996-02-28 1998-04-03 Roussel Uclaf Nouveaux derives de l'erythromycine, leur procede de preparation et leur application comme medicaments
US5719272A (en) 1996-04-02 1998-02-17 Abbott Laboratories 2'-protected 3'-dimethylamine, 9-etheroxime erythromycin A derivatives
IL128681A0 (en) * 1996-09-04 2000-01-31 Abbott Lab 6-O substituted ketolides having antibacterial activity
AU5597098A (en) 1996-12-13 1998-07-03 Eli Lilly And Company Inhibitors of the enzymatic activity of psa
US6407074B1 (en) 1997-06-11 2002-06-18 Pfizer Inc C-4″-substituted macrolide derivatives
HN1998000086A (es) 1997-06-11 1999-03-08 Pfizer Prod Inc Derivados de 9 - desofo - 9 aza - 9a - homoeritromicina a - c - 4 sustituidos.
EP0988308A1 (en) 1997-06-11 2000-03-29 Pfizer Products Inc. 9-oxime erythromycin derivatives
HN1998000074A (es) 1997-06-11 1999-01-08 Pfizer Prod Inc Derivados de macrolidos c-4 sustituidos
HN1998000159A (es) 1997-10-29 1999-02-09 Monsanto Co Derivados de 9- amino - 3 ceto eritromicina
IL135792A0 (en) 1997-12-01 2001-05-20 Abbott Lab 6-o-alkyl derivatives of erythronolide b
PT1421939E (pt) * 1998-03-26 2010-07-12 Astellas Pharma Inc Preparaã†o da libertaã†o sustentada de um composto de macrëlido como tracolimus
FR2777282B1 (fr) * 1998-04-08 2001-04-20 Hoechst Marion Roussel Inc Nouveaux derives de la 2-fluoro 3-de((2,6-dideoxy 3-c-methyl 3-0-methyl-alpha-l-ribohexopyranosyl) oxyl) 6-o-methyl 3-oxo erythromycine, leur procede de preparation et leur application a la synthese de principes actifs de medicaments
US6020521A (en) * 1998-08-26 2000-02-01 Abbott Laboratories Macrolide LHRH antagonists
US6387885B1 (en) 1998-08-26 2002-05-14 Abbott Laboratories 3′,3′-N-bis-desmethyl-3′-N-cycloalkyl erythromycin derivatives as LHRH antagonists
FR2785612A1 (fr) 1998-11-10 2000-05-12 Hoechst Marion Roussel Inc Nouveaux derives de l'erythromycine, leur procede de preparation et leur application comme medicaments
FR2786188B1 (fr) 1998-11-24 2002-10-31 Hoechst Marion Roussel Inc Nouveaux derives de l'erythromycine, leur procede de preparation et leur applicaion comme medicaments
KR100317907B1 (ko) 1998-11-24 2001-12-24 김 완 주 신규한 중간체, 이를 이용한 마크로라이드계 항생제의제조방법
ATE344269T1 (de) 1998-12-10 2006-11-15 Pfizer Prod Inc Carbamat und carbazat ketolid antibiotika
EP1147121B1 (en) 1999-01-27 2003-12-17 Pfizer Products Inc. Ketolide antibiotics
CA2411293A1 (en) 1999-01-28 2000-07-28 Pfizer Products Inc. Novel azalides and methods of making same
FR2789392B1 (fr) 1999-02-04 2001-10-05 Hoechst Marion Roussel Inc Nouveaux derives de l'erythromycine, leur procede de preparation et leur application comme medicaments
JP2000351794A (ja) 1999-04-08 2000-12-19 Hokuriku Seiyaku Co Ltd エリスロマイシン誘導体
AR023264A1 (es) 1999-04-08 2002-09-04 Hokuriku Pharmaceutical Derivados de eritromicina
AU773678B2 (en) 1999-04-16 2004-06-03 Kosan Biosciences, Inc. Macrolide antiinfective agents
AU4354900A (en) 1999-04-16 2000-11-02 Kosan Biosciences, Inc. Ketolide antibacterials
US6395300B1 (en) 1999-05-27 2002-05-28 Acusphere, Inc. Porous drug matrices and methods of manufacture thereof
US6420535B1 (en) * 1999-06-07 2002-07-16 Abbott Laboratories 6-O-carbamate ketolide derivatives
US6437106B1 (en) 1999-06-24 2002-08-20 Abbott Laboratories Process for preparing 6-o-substituted erythromycin derivatives
AU6183700A (en) 1999-08-06 2001-03-05 Taisho Pharmaceutical Co., Ltd. Erythromycin a derivatives
WO2001010787A1 (en) 1999-08-09 2001-02-15 Eric Au An apparatus for treating wastewater
US6096922A (en) 1999-11-01 2000-08-01 Air Products And Chemicals, Inc. Process for the synthesis of dialkyl, diaryl, and arylalkyl aminosulfur trifluorides
KR100336447B1 (ko) 1999-11-24 2002-05-15 민경윤 클라리스로마이신의 개선된 제조방법
JP2001261694A (ja) 2000-03-06 2001-09-26 Pfizer Prod Inc ケトライド抗生物質
ES2242668T3 (es) 2000-03-15 2005-11-16 Hanmi Pharm. Co., Ltd. Metodo para obtener claritromicina en cristales de forma ii.
NZ523693A (en) 2000-07-10 2004-08-27 Chiron Corp Macrolide formulations for inhalation and methods of treatment of endobronchial infections
US20020115621A1 (en) 2000-08-07 2002-08-22 Wei-Gu Su Macrolide antibiotics
GB0031312D0 (en) 2000-12-21 2001-02-07 Glaxo Group Ltd Macrolides
EP1320355B1 (en) 2001-05-18 2006-04-05 Chiron Corporation System for delivering a tobramycin formulation
EP1404693A2 (en) 2001-07-03 2004-04-07 Chiron Corporation C12 modified erythromycin macrolides and ketolides having antibacterial activity
US20030176327A1 (en) * 2001-10-25 2003-09-18 Cassell Gail Houston Antibiotics for treating biohazardous bacterial agents
AR038576A1 (es) 2002-02-22 2005-01-19 Pharmacia Corp Formulaciones de drogas antibioticas oftalmicas que contienen un compuesto de ciclodextrina y cloruro de cetil piridinio
ES2346646T5 (es) 2002-05-30 2018-02-15 The Scripps Research Institute Ligación catalizada con cobre de azidas y acetilenos
AU2003269889B2 (en) 2002-06-17 2007-04-19 Epigenesis Pharmaceuticals, Llc Dihydrate dehydroepiandrosterone and methods of treating asthma or chronic obstructive pulmonary disease using compositions thereof
US7091187B2 (en) 2002-07-08 2006-08-15 Pliva-Istrazivacki Institut D.O.O. Compounds, compositions and methods for treatment of inflammatory diseases and conditions
US7091196B2 (en) * 2002-09-26 2006-08-15 Rib-X Pharmaceuticals, Inc. Bifunctional heterocyclic compounds and methods of making and using same
ITMI20022292A1 (it) 2002-10-29 2004-04-30 Zambon Spa 9a-azalidi ad attivita' antiinfiammatoria.
WO2004096823A2 (en) 2003-04-25 2004-11-11 Chiron Corporation Novel ketolide derivatives
WO2004096822A2 (en) 2003-04-25 2004-11-11 Chiron Corporation Pyridyl substituted ketolide antibiotics
EP1628989B1 (en) 2003-05-13 2006-12-20 Glaxo Group Limited Novel 14 and 15 membered-ring compounds
WO2005007143A2 (en) 2003-07-14 2005-01-27 The Board Of Trustees Of The University Of Illinois Use of makrolides and ketolides for the treatment of tuberculosis
US7457520B2 (en) 2003-07-24 2008-11-25 Time Warner Cable, Inc. Technique for providing a virtual digital video recorder service through a communications network
GB0402578D0 (en) 2004-02-05 2004-03-10 Cambridge Theranostics Ltd Methods of treatment of atherosclerosis
US20060116336A1 (en) * 2004-03-17 2006-06-01 American Pharmaceutical Partners, Inc. Lyophilized azithromycin formulation
US7468428B2 (en) 2004-03-17 2008-12-23 App Pharmaceuticals, Llc Lyophilized azithromycin formulation
PL1742957T3 (pl) 2004-04-28 2008-05-30 Alembic Ltd Sposób otrzymywania telitromycyny
ES2331739T3 (es) 2004-05-06 2010-01-14 Glaxosmithkline Istrazivacki Centar Zagreb D.O.O. Macrolidos que contienen enlaces ester utiles para el tratamiento de infecciones microbianas.
US20080287376A1 (en) 2004-07-28 2008-11-20 Mohammad Salman Ketolide Derivatives as Antibacterial Agents
GB0424958D0 (en) 2004-11-11 2004-12-15 Glaxo Group Ltd Novel compounds
GB0424959D0 (en) 2004-11-11 2004-12-15 Glaxo Group Ltd Novel compounds
EP1841437B1 (en) 2005-01-14 2009-04-29 GlaxoSmithKline istrazivacki centar Zagreb d.o.o. 9a-carbamoyl and thiocarbamoyl azalides with antimalarial activity
DE602006016231D1 (de) * 2005-01-14 2010-09-30 Glaxosmithkline Zagreb 9a-carbamoyl-y-aminopropyl- und 9a-thiocarbamoyl-y-aminopropyl-azalide mit antimalaria-aktivität
WO2006106440A1 (en) 2005-01-14 2006-10-12 Glaxosmithkline Istrazivacki Centar Zagreb D.O.O. Macrolide compounds containing biotin and photo-affinity group for macrolide target identification
EP1868434A4 (en) 2005-03-22 2011-10-26 Azevan Pharmaceuticals Inc BETA-LACTAMYL ALKANIC ACIDS FOR THE TREATMENT OF PREMIERSTRUELLEN FAULTS
CA2614412A1 (en) 2005-07-07 2007-01-18 Elan Pharma International, Limited Nanoparticulate clarithromycin formulations
ES2726942T3 (es) 2005-07-19 2019-10-10 Azevan Pharmaceuticals Inc Antagonista de vasopresina de tipo beta-lactamil fenilalanina, cisteína y serina
DK1945654T3 (en) 2005-10-31 2015-11-30 Leo Pharma As CREATING A antibiotic, CRYSTALLINE fusidic
GB0522715D0 (en) 2005-11-08 2005-12-14 Helperby Therapeutics Ltd New use
US20070167382A1 (en) 2005-11-15 2007-07-19 Nina Finkelstein Crystalline and amorphous forms of telithromycin
EP1954294A2 (en) 2005-11-23 2008-08-13 Ranbaxy Laboratories Limited Use of macrolide derivatives for treating acne
WO2007060518A2 (en) * 2005-11-23 2007-05-31 Ranbaxy Laboratories Limited Ketolide derivatives as antibacterial agents
DOP2006000268A (es) 2005-12-22 2007-07-31 Pfizer Prod Inc Agentes antibacterianos
CN101045063B (zh) 2006-03-28 2011-01-26 广州朗圣药业有限公司 注射用克拉霉素水溶性制剂
CN103193840A (zh) 2006-05-01 2013-07-10 大正制药株式会社 大环内酯衍生物
AU2007256844A1 (en) 2006-06-05 2007-12-13 Auspex Pharmaceuticals, Inc. Preparation and utility of substituted erythromycin analogs
DE102006036199B4 (de) * 2006-08-03 2016-01-07 Deere & Company Förderzusammenbau und Presse
CN101129383B (zh) 2006-08-25 2014-04-02 天津和美生物技术有限公司 含氨基糖苷类抗生素的抗生素复方
JP5698979B2 (ja) 2007-10-25 2015-04-08 センプラ ファーマシューティカルズ，インコーポレイテッド マクロライド系抗菌剤の調製プロセス
US20090209547A1 (en) * 2008-02-15 2009-08-20 In Jong Kim C-8 halogenated macrolides
HRP20160222T1 (hr) * 2008-10-24 2016-04-08 Cempra Pharmaceuticals, Inc. Biozaštite uporabom makrolida koji sadrže triazol
US9814657B2 (en) 2009-04-27 2017-11-14 Premier Dental Products Company Buffered microencapsulated compositions and methods
CA2767614C (en) 2009-07-13 2019-01-15 Cempra Pharmaceuticals Inc. Fusidic acid dosing regimens for treatment of bacterial infections
WO2011032052A1 (en) 2009-09-10 2011-03-17 Cempra Pharmaceuticals, Inc. Methods for treating malaria, tuberculosis and mac diseases
US20110119604A1 (en) 2009-11-19 2011-05-19 Clevest Solutions Inc. System and method for a configurable and extensible allocation and scheduling tool
JP5890785B2 (ja) 2010-03-10 2016-03-22 センプラ ファーマシューティカルズ，インコーポレイテッド マクロライド抗生物質の非経口製剤
KR102006200B1 (ko) 2010-03-22 2019-08-01 셈프라 파마슈티컬스, 인크. 매크로라이드의 결정 형태들 및 그 용도들
EP2571506B1 (en) 2010-05-20 2017-05-10 Cempra Pharmaceuticals, Inc. Processes for preparing macrolides and ketolides and intermediates therefor
US8247394B2 (en) 2010-06-02 2012-08-21 Cempra Pharmaceuticals Inc. Methods of treating urethritis and related infections using fusidic acid
US9260473B2 (en) 2010-07-19 2016-02-16 Virginia Commonwealth University Bivalent multifunctional ligands targeting Aβ oligomers as treatment for Alzheimer's disease
CA2812044A1 (en) 2010-08-30 2012-03-08 Cempra Pharmaceuticals Inc. Methods of treating bacterial infections through pulmonary delivery of fusidic acid
KR20130120458A (ko) 2010-09-10 2013-11-04 셈프라 파마슈티컬스, 인크. 질환을 치료하기 위한 수소결합 형성 플루오로 케토라이드
WO2012042534A2 (en) 2010-09-28 2012-04-05 Glenmark Generics Limited Processes for the preparation of r-sitagliptin and intermediates thereof
JP6072778B2 (ja) 2011-05-23 2017-02-01 シーイーエム—１０２ ファーマシューティカルズ，インコーポレイテッド フシジン酸を含む組成物およびそのためのパッケージ
CA2833241C (en) 2011-08-27 2015-05-12 Wockhardt Limited 1,6-diazabicyclo [3,2,1] octan-7-one derivatives and their use in the treatment of bacterial infections
CN103998442B (zh) 2011-08-29 2016-09-14 无限药品股份有限公司 杂环化合物及其用途
WO2013059610A1 (en) 2011-10-20 2013-04-25 Trius Therapeutics, Inc. Therapeutic combination of daptomycin and protein synthesis inhibitor antibiotic, and methods of use
WO2013148891A1 (en) 2012-03-27 2013-10-03 Cempra Pharmaceuticals, Inc. Parenteral formulations for administering macrolide antibiotics
EP2968801B1 (en) 2013-03-14 2018-09-26 Cempra Pharmaceuticals, Inc. Methods for treating respiratory diseases and formulations therefor
CN105188712A (zh) 2013-03-15 2015-12-23 森普拉制药公司 用于制备大环内酯抗菌剂的收敛方法
AU2014248014B2 (en) 2013-04-04 2018-11-08 President And Fellows Of Harvard College Macrolides and methods of their preparation and use
RU2016133471A (ru) 2014-02-14 2018-03-19 Семпра Фармасьютикалс, Инк. Композиции и способы для лечения диабета и заболеваний печени
WO2015181723A1 (en) 2014-05-27 2015-12-03 Dipharma Francis S.R.L. Azidoalkylamine salts and their use as intermediates
RU2017104163A (ru) 2014-08-05 2018-09-06 Семпра Фармасьютикалз, Инк. Порошкообразные составы пероральных суспензий антибактериальных агентов
EP3265100A4 (en) 2015-03-06 2019-01-09 Cempra Pharmaceuticals Inc. PROCESS FOR THE PREPARATION OF FLUOROCHETOLIDES

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060100164A1 (en) * 2003-03-10 2006-05-11 Chang-Hsing Liang Novel antibacterial agents

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
SUMERKAN, B., ET AL, Salisbury Medical Bulletin, 1996, number 87 special supplement, page 138 [retrieved on 17 July 2014]. Retrieved from the Internet *

Also Published As

Publication number Publication date
WO2010048600A1 (en) 2010-04-29
EP2362727A4 (en) 2012-05-02
US8796232B2 (en) 2014-08-05
US20110237534A1 (en) 2011-09-29
JP5922210B2 (ja) 2016-05-24
JP5908569B2 (ja) 2016-04-26
US20150111845A1 (en) 2015-04-23
CN102245022A (zh) 2011-11-16
AU2016202707A1 (en) 2016-05-19
EP2358379B1 (en) 2015-12-16
JP2015078203A (ja) 2015-04-23
US9901592B2 (en) 2018-02-27
EP2358379A4 (en) 2012-05-09
US9072759B2 (en) 2015-07-07
ES2565083T3 (es) 2016-03-31
US8791080B2 (en) 2014-07-29
EP2365747B1 (en) 2018-04-11
AU2009308181A1 (en) 2010-04-29
CN102223794A (zh) 2011-10-19
EP2358379A1 (en) 2011-08-24
AU2009308180A1 (en) 2010-04-29
US20160082028A1 (en) 2016-03-24
JP6002185B2 (ja) 2016-10-05
JP2021193117A (ja) 2021-12-23
CN107854477A (zh) 2018-03-30
JP5715569B2 (ja) 2015-05-07
JP2020023544A (ja) 2020-02-13
CN102245195A (zh) 2011-11-16
CN102223794B (zh) 2017-12-22
ES2676168T3 (es) 2018-07-17
JP2012506872A (ja) 2012-03-22
HRP20160222T1 (hr) 2016-04-08
JP2016166224A (ja) 2016-09-15
AU2009308180B2 (en) 2016-01-07
US20180369262A1 (en) 2018-12-27
JP7171860B2 (ja) 2022-11-15
EP2365747A1 (en) 2011-09-21
US20150105339A1 (en) 2015-04-16
CN105616437A (zh) 2016-06-01
JP2014237710A (ja) 2014-12-18
AU2009308182A1 (en) 2010-04-29
CN102245195B (zh) 2016-01-13
HK1252140A1 (zh) 2019-05-17
EP2362727A1 (en) 2011-09-07
US9439918B2 (en) 2016-09-13
JP5711135B2 (ja) 2015-04-30
JP2012506871A (ja) 2012-03-22
EP2365747A4 (en) 2012-06-13
JP2018115177A (ja) 2018-07-26
JP2012506870A (ja) 2012-03-22
SI2358379T1 (sl) 2016-05-31
EP3031460A1 (en) 2016-06-15
US20110195920A1 (en) 2011-08-11
ES2677007T3 (es) 2018-07-27
AU2009308181B2 (en) 2015-12-03
EP2362727B1 (en) 2018-04-11
US20110201566A1 (en) 2011-08-18
JP6309995B2 (ja) 2018-04-11
WO2010048601A1 (en) 2010-04-29
WO2010048599A1 (en) 2010-04-29
JP2015061858A (ja) 2015-04-02
US9669046B2 (en) 2017-06-06
DK2358379T3 (en) 2016-03-07
JP5602748B2 (ja) 2014-10-08

Similar Documents

Publication Publication Date Title
AU2009308182B2 (en) Biodefenses using triazole-containing macrolides
WO2007097940A2 (en) Reca inhibitors with antibiotic activity, compositions and methods of use
HK1224595A1 (en) Biodefenses using triazole-containing macrolides
HK1224595A (en) Biodefenses using triazole-containing macrolides
HK1224922A (en) Biodefenses using triazole-containing macrolides
HK1224922A1 (en) Biodefenses using triazole-containing macrolides
EP3769622A1 (en) Antimycotic
EP3769815A1 (en) Antimycotic

Legal Events

Date Code Title Description
DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE NAME OF THE INVENTOR TO READ FERNANDES, PRABHAVATHI

FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired